Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

por Merin, Noah M., Kelly, Kevin R.
Publicado 2014

Autophagy as a target for cancer therapy: new developments

por Carew, Jennifer S, Kelly, Kevin R, Nawrocki, Steffan T
Publicado 2012

Oncolytic Viruses for Multiple Myeloma Therapy

por Calton, Christine M., Kelly, Kevin R., Anwer, Faiz, Carew, Jennifer S., Nawrocki, Steffan T.
Publicado 2018

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

por Kelly, Kevin R, Ecsedy, Jeffrey, Medina, Ernest, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Nawrocki, Steffan T, Giles, Francis J, Carew, Jennifer S
Publicado 2011

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

por Kelly, Kevin R., Espitia, Claudia M., Zhao, Weiguo, Wendlandt, Erik, Tricot, Guido, Zhan, Fenghuang, Carew, Jennifer S., Nawrocki, Steffan T.
Publicado 2015

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy

por Kelly, Kevin R., Espitia, Claudia M., Zhao, Weiguo, Wu, Kaijin, Visconte, Valeria, Anwer, Faiz, Calton, Christine M., Carew, Jennifer S., Nawrocki, Steffan T.
Publicado 2017

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

por Oki, Yasuhiro, Kelly, Kevin R, Flinn, Ian, Patel, Manish R., Gharavi, Robert, Ma, Anna, Parker, Jefferson, Hafeez, Amir, Tuck, David, Younes, Anas
Publicado 2017

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms

por Visconte, Valeria, Przychodzen, Bartlomiej, Han, Yingchun, Nawrocki, Steffan T., Thota, Swapna, Kelly, Kevin R., Patel, Bhumika J., Hirsch, Cassandra, Advani, Anjali S., Carraway, Hetty E., Sekeres, Mikkael A., Maciejewski, Jaroslaw P., Carew, Jennifer S.
Publicado 2016

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azac...

por Visconte, Valeria, Nawrocki, Steffan T., Espitia, Claudia M., Kelly, Kevin R., Possemato, Anthony, Beausoleil, Sean A., Han, Yingchun, Carraway, Hetty E., Nazha, Aziz, Advani, Anjali S., Maciejewski, Jaroslaw P., Sekeres, Mikkael A., Carew, Jennifer S.
Publicado 2015

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

por Kelly, Kevin R., Shea, Thomas C., Goy, André, Berdeja, Jesus G., Reeder, Craig B., McDonagh, Kevin T., Zhou, Xiaofei, Danaee, Hadi, Liu, Hua, Ecsedy, Jeffrey A., Niu, Huifeng, Benaim, Ely, Padmanabhan Iyer, Swaminathan
Publicado 2013

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

por Daver, Naval G., Dail, Monique, Garcia, Jacqueline S., Jonas, Brian A., Yee, Karen W. L., Kelly, Kevin R., Vey, Norbert, Assouline, Sarit, Roboz, Gail J., Paolini, Stefania, Pollyea, Daniel A., Tafuri, Agostino, Brandwein, Joseph M., Pigneux, Arnaud, Powell, Bayard L., Fenaux, Pierre, Olin, Rebecca L., Visani, Giuseppe, Martinelli, Giovanni, Onishi, Maika, Wang, Jue, Huang, Weize, Green, Cherie, Ott, Marion G., Hong, Wan-Jen, Konopleva, Marina Y., Andreeff, Michael
Publicado 2023